CSL shares (ASX: CSL) reclaimed the A$180 mark on Wednesday, closing at A$181.99 after a 1.85% gain that bulls will be looking to build on, and break out of the consolidation phase.
After spending the first four trading sessions of October below A$180, CSL shares put up a solid recovery, adding A$3.31 to close at A$181.99. The session’s volume of 1.41 million shares, equivalent to 1.58 times the stock’s average daily volume, underscored the strength in the move, as buyers stepped in.
Critically, the stock had found technical support at its 30-day SMA of A$175.90, a level that held firm during the brief early-month pullback. That bounce, combined with a RSI that had cooled from overbought territory above 70 down to a more sustainable reading of 62, has created meaningful technical headroom for a potential continuation higher. There was no major company-specific news on the day to explain the move, reinforcing the interpretation that this is a positioning-driven recovery rather than a reaction to a single catalyst.
The session’s close above A$180 is notable in a broader context. CSL endured a bruising first half of 2026, falling approximately 45% to a 52-week low near A$90 before staging a remarkable recovery of close to 93% through the second half of the year. Wednesday’s price action represents a consolidation of those gains rather than a new leg higher, though the volume profile suggests markets are watching the A$180 level closely as a line of support.
What Lay Ahead
The recovery in CSL’s core plasma business is a key pillar of the bull case. Demand for immunoglobulin products, including PRIVIGEN, has been recovering steadily as plasma collection volumes normalise post-pandemic, and management has pointed to improving yield efficiency across its collection network. These structural tailwinds are expected to support margin expansion through 2028 and 2029, giving the earnings recovery story a multi-year runway.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
From a technical standpoint, the reclaim of A$180 on above-average volume is a bullish sign. The RSI reset to 62 leaves room for further upside without the stock entering overbought territory immediately, and the 30-day SMA at A$175.90 has established itself as a credible near-term support level. A sustained hold above A$180 would be seen as confirmation that the consolidation phase has resolved to the upside.
The CSL share price reclaiming a A$180 handle on strong volume is an encouraging sign after a difficult 18 months. There remains plenty for both bulls and bears to get behind, and after a year so far that has delivered almost a trim in half, and then a doubling, there could be further volatility in this one yet. Heading into the final two trading sessions, this one has been a week for the bulls so far, but can three consecutive days of gains turn to four, or will bears test the strength of this psychological level once more?
Bull Case:
- Technical breakout above A$180 confirmed by 1.58x average daily volume signals institutional accumulation.
- Plasma immunoglobulin demand recovery and improving yield efficiency support multi-year margin expansion.
- A$1.1 billion buyback and US$220 million cost savings target drive EPS growth despite flat revenue.
- Lixudebart partnership expands high-margin rare disease pipeline with milestone-based downside protection.
Bear Case:
- Consensus price targets near A$182.85 leave limited near-term upside without fresh earnings upgrades.
- CSL Vifor revenues projected to fall approximately 25% in FY27, weighing on top-line growth.
- US$355 million Alentis upfront payment adds cash flow pressure during active corporate restructuring.
- FY27 earnings growth relies heavily on cost cuts rather than organic revenue expansion.
